PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers is a research paper published in ESMO Open (2021). On theSindex it has a DataRank of 0.564. It has been cited 42 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.564
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: CA088084
National Institutes of Health
Grant: 1UL1 TR003167
National Institutes of Health
Grant: P30 CA016672
National Center for Advancing Translational Sciences
Grant: UL1 TR000371
Cancer Prevention and Research Institute of Texas
Grant: RP150535
National Institutes of Health
Grant: 3UL1TR003167-02S4
Center for Clinical and Translational Sciences (CCTS)
National Institutes of Health
Grant: 1ZIATR000371-03
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5K12CA088084-02
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM
National Institutes of Health
Grant: 4UL1TR000371-10
Center for Clinical and Translational Sciences (CCTS)
FWCI
1.81
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals